Stoke Therapeutics, Inc. (STOK)

Over the past six months, Stoke Therapeutics' stock experienced several notable events. In November 2025, the company received an upgrade to a "Buy" rating. In December 2025, the stock surged due to strong Dravet syndrome data for zorevunersen and an advancing pipeline. In January 2026, the stock tumbled after the company announced updated timelines for its Phase 3 EMPEROR study. In February 2026, Stoke Therapeutics announced the first patient dosed in a Phase 1 study of STK-002 for ADOA. In March 2026, data demonstrating the potential for disease modification in Dravet syndrome with zorevunersen was published, but the stock experienced a pre-market gap down following quarterly financial updates and reports of insider selling. In April 2026, Stoke Therapeutics announced inducement grants and appointed Clare Kahn, Ph.D., to its Board of Directors, with investor attention on strong full-year 2025 results and pipeline progress, tempered by continued insider selling.

Only six years of stock data are available for Stoke Therapeutics, Inc., which is considered insufficient to reliably establish a comprehensive seasonal demand profile. However, the seasonal timeframe for STOK is noted to be in line with the broader Healthcare sector's period of seasonal strength, which typically runs from April 25 to December 4.

Stoke Therapeutics, Inc. (STOK) is a biotechnology company focused on addressing severe genetic diseases by upregulating protein expression using RNA-based medicines. The company utilizes its TANGO approach to develop ASOs that selectively restore protein levels. Its major product candidates include Zorevunersen (STK-001) for Dravet syndrome and STK-002 for autosomal dominant optic atrophy (ADOA). Stoke's initial focus is on haploinsufficiency and diseases affecting the central nervous system and the eye.

Stoke Therapeutics is headquartered in Bedford, Massachusetts, with additional offices in Cambridge, Massachusetts. The company has a global development and commercialization strategy for zorevunersen, retaining exclusive rights in the United States, Canada, and Mexico, while collaborating with Biogen Inc. for all other territories worldwide.

Stoke Therapeutics' brand reputation is influenced by its clinical progress and financial performance. Positive data for zorevunersen in The New England Journal of Medicine bolstered its scientific and clinical reputation. Recent insider selling has drawn investor scrutiny, but analysts generally maintain a "Moderate Buy" consensus, indicating a positive overall market perception.

Stoke Therapeutics has a mixed ownership structure comprising institutional, insider, and retail investors. Major institutional owners include Fmr Llc, RTW Investments, LP, and BlackRock, Inc. Seth Loring Harrison is the largest individual shareholder, owning 57.39% of the company. Insider ownership is substantial, indicating that management and key personnel have a vested interest in the company's performance.